Cefminox
Systematic (IUPAC) name | |
---|---|
(6R,7S)-7-(((((2S)-2-amino-2-carboxyethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
| |
IM, IV | |
Identifiers | |
84305-41-9 | |
J01DC12 | |
PubChem | CID 71141 |
ChemSpider | 64286 |
UNII | PW08Y13465 |
KEGG | D07642 |
ChEMBL | CHEMBL1276342 |
Chemical data | |
Formula | C16H21N7O7S3 |
519.57 g/mol | |
SMILES
| |
| |
(what is this?) (verify) |
Cefminox (INN) is a second-generation cephalosporin antibiotic.[1][2]
Spectrum
Cefminox is a broad-spectrum, bactericidal cephalosporin antibiotic. It is especially effective against Gram-negative and anaerobic bacteria. The following represents MIC data for a few medically significant microorganisms.
- Clostridium difficile: 2 - 4 µg/ml
- Escherichia coli: 0.125 - 16 µg/ml
- Pseudomonas aeruginosa: 256 µg/ml
References
- ↑ Torres, A. J.; Valladares, L. D.; Jover, J. M.; Sánchez-Pernaute, A.; Frías, J.; Carcas, A. J.; Coronel, P.; Ródenas, E.; Pérez-Balcabao, I.; Fernández-Roblas, R.; Moreno, M.; Balibrea, J. L. (2000). "Cefminox versus metronidazole plus gentamicin intra-abdominal infections: A prospective randomized controlled clinical trial". Infection 28 (5): 318–322. doi:10.1007/s150100070027. PMID 11073141.
- ↑ Patentdocs: Reaction Medium For Methicillin-Resistant Staphylococcus Aureus (Mrsa) Bacteria
- ↑ http://www.toku-e.com/Assets/MIC/Cefminox%20sodium.pdf
|